{
    "clinical_study": {
        "@rank": "149778", 
        "arm_group": [
            {
                "arm_group_label": "HBsAg negative kidney allograft donor"
            }, 
            {
                "arm_group_label": "HBsAg positive kidney allograft donor", 
                "description": "HBsAg positive kidney allograft donor"
            }
        ], 
        "brief_summary": {
            "textblock": "To determine the safety of using kidney organ from hepatitis B surface antigen positive\n      donor, the author conducted the single-center, prospective study of  the use of these\n      kidneys for recipients who have protective level of hepatitis B surface antibodies."
        }, 
        "brief_title": "Hepatitis B Antigen Kidney Graft Into Protective Level Hepatitis B Antibody Recipients", 
        "condition": [
            "HBsAg(+) Donor Kidney Allograft", 
            "HBsAg(-) Donor Kidney Allograft"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B"
            ]
        }, 
        "detailed_description": {
            "textblock": "The kidney transplant registry was conducted in KCMH since the year of 2000 until the\n      present.\n\n      The inclusion criterion was:\n\n        -  All kidney allograft recipients who received at least one month after transplantation.\n\n        -  All kidney recipients who already had the protective antibody against hepatitis B virus\n           infection defined by anti-HBs titer above 100 mIU/mL at pre-transplantation period.\n\n      The exclusion criterion was:\n\n        -  The recipients with positive hepatitis C virus antibody.\n\n        -  The recipients who had received a previous or simultaneous non-kidney solid organ\n           transplant.\n\n        -  The recipients those lost to follow-up.\n\n      Study group:\n\n        -  The recipients who received kidney allograft from the HBsAg(+) donor.\n\n      Control group:\n\n        -  The recipients who received kidney allograft from the HBsAg(-) donor.\n\n      According to the Thai Red Cross National Organ Donation and our institute's policy, the\n      HBsAg(+) kidney allografts were distributed to only and informed consent.\n\n      Data collection:\n\n        -  Baseline characteristic data e.g. donor and recipient age, donor and recipient gender,\n           HLA, PRA, anti-HBs titer, immunity against HBV status (both natural and\n           vaccinated),immunosuppressive regimens were collected.\n\n        -  The recipients were prospective followed up at month 3, 6, 9, 12, 18, 24, 36, 48, 60,\n           72, 84, 96, 108, 120.\n\n        -  Clinical data including jaundice, hepatitis, graft rejection were collected\n\n        -  Laboratory data of HBsAg, anti-HBc, HBV DNA, SGOT, SGOT, eGFR were collected.\n\n        -  Pathological data of allograft biopsy at month 12 and 24 were retrieved.\n\n      Outcomes:\n\n        -  Primary outcome: hepatitis B transmission rate.\n\n        -  Secondary outcome: graft survival, patient survival."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "The inclusion criterion was:\n\n          -  All kidney allograft recipients who received at least one month after\n             transplantation.\n\n          -  All kidney recipients who already had the protective antibody against hepatitis B\n             virus infection defined by anti-HBs titer above 100 mIU/mL at pre-transplantation\n             period.\n\n        The exclusion criterion was:\n\n          -  The recipients with positive hepatitis C virus antibody.\n\n          -  The recipients who had received a previous or simultaneous non-kidney solid organ\n             transplant.\n\n          -  The recipients those lost to follow-up."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "All kidney transplant recipients from January 1, 2000 until the present (upto year 2013)\n        were prospective follow-up."
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02044588", 
            "org_study_id": "WWC-001"
        }, 
        "intervention": {
            "arm_group_label": "HBsAg positive kidney allograft donor", 
            "intervention_name": "HBsAg positive kidney allograft donor", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": "Hepatitis B Antibodies"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HBsAg(+) donor", 
            "HBsAg(-) donor", 
            "Anti-hepatitis B antibody", 
            "Kidney allograft"
        ], 
        "lastchanged_date": "January 22, 2014", 
        "location": {
            "contact": {
                "email": "wiwatmd@hotmail.com", 
                "last_name": "Wiwat Chancharoenthana, MD, Msc"
            }, 
            "facility": {
                "address": {
                    "city": "Bangkok", 
                    "country": "Thailand", 
                    "zip": "10330"
                }, 
                "name": "Wiwat Chancharoenthana"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_groups": "2", 
        "official_title": "The Outcomes of Kidney Transplantation Between Recipients Receiving Graft From Donors With Positive and Negative HBsAg", 
        "other_outcome": {
            "description": "The patient survival rate was determined by Kaplan-Meyer survival analysis.", 
            "measure": "Patient survival rate", 
            "safety_issue": "Yes", 
            "time_frame": "January 2000 to December 2013"
        }, 
        "overall_contact": {
            "email": "wiwatmd@hotmail.com", 
            "last_name": "Wiwat Chancharoenthana, MD, MSc"
        }, 
        "overall_official": {
            "affiliation": "Chulalongkorn University", 
            "last_name": "Wiwat Chancharoenthana, MD, MSc", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Thailand: Ethical Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The hepatitis B transmission rate was determined at month 3, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120 by using:\nClinical data including jaundice, hepatitis, acute liver failure.\nLaboratory data of HBsAg, anti-HBc, HBV DNA, SGOT, SGOT.\nRadiological data of liver ultrasonography.", 
            "measure": "Hepatitis B transmission rate", 
            "safety_issue": "Yes", 
            "time_frame": "January 2000 to December 2013"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02044588"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chulalongkorn University", 
            "investigator_full_name": "Wiwat Chancharoenthana", 
            "investigator_title": "Division of Nephrology, Department of Medicine, Faculty of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "The graft survival rate was determined by Kaplan-Meyer survival analysis.", 
            "measure": "Graft survival rate", 
            "safety_issue": "No", 
            "time_frame": "January 2000 to December 2013"
        }, 
        "source": "Chulalongkorn University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chulalongkorn University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2000", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "10 Years", 
        "verification_date": "January 2014"
    }
}